PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

Section

Manufacturing

Capacity, CDMO strategy, inspections, supply bottlenecks, and manufacturing constraints that shape commercial reality.

1 article · Last updated 2026-05-13

Manufacturing· May 9, 2026 · 4 min read

GLP-1 manufacturing capacity is now a commercial strategy problem

For GLP-1 products, demand is only half the story. Drug substance, fill-finish, device assembly, inspections, and supply reliability now shape access and share.

By Ran Chen#GLP-1 #Manufacturing Capacity #Coverage Access